Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 7;10(10):4789-98.
doi: 10.1021/pr2005583. Epub 2011 Sep 13.

Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation

Affiliations

Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation

Dennis W Szymanski et al. J Proteome Res. .

Abstract

The lack of experimental characterization of the structures and ligand-binding motifs of therapeutic G-protein coupled receptors (GPCRs) hampers rational drug discovery. The human cannabinoid receptor 2 (hCB2R) is a class-A GPCR and promising therapeutic target for small-molecule cannabinergic agonists as medicines. Prior mutational and modeling data constitute provisional evidence that AM-841, a high-affinity classical cannabinoid, interacts with cysteine C6.47(257) in hCB2R transmembrane helix 6 (TMH6) to afford improved hCB2R selectivity and unprecedented agonist potency. We now apply bottom-up mass spectrometry (MS)-based proteomics to define directly the hCB2R-AM-841 interaction at the amino-acid level. Recombinant hCB2R, overexpressed as an N-terminal FLAG-tagged/C-terminal 6His-tagged protein (FLAG-hCB2R-6His) with a baculovirus system, was solubilized and purified by immunochromatography as functional receptor. A multiplex multiple reaction monitoring (MRM)-MS method was developed that allowed us to observe unambiguously all seven discrete TMH peptides in the tryptic digest of purified FLAG-hCB2R-6His and demonstrate that AM-841 modifies hCB2R TMH6 exclusively. High-resolution mass spectra of the TMH6 tryptic peptide obtained by Q-TOF MS/MS analysis demonstrated that AM-841 covalently and selectively modifies hCB2R at TMH6 cysteine C6.47(257). These data demonstrate how integration of MS-based proteomics into a ligand-assisted protein structure (LAPS) experimental paradigm can offer guidance to structure-enabled GPCR agonist design.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Chemical structure of AM-841. (b) Saturation-binding assay of [3H]CP-55940 radioligand to FLAG-hCB2R-6His in membranes from Sf-21 cells overexpressing this receptor. Membrane incubation with AM-841 prior to [3H]CP-55940 binding (▲) reduced the receptor Bmax by ~ 75% relative to the Bmax in membranes not exposed to AM-841 (■). Data are means ± SEM of at least two independent experiments performed in duplicate. (c) Western blot analysis of the of the purified FLAG-hCB2R-6His preparation with anti-FLAG antibody detection. M, monomer; D, dimer; O, oligomers.
Figure 2
Figure 2
LC-MS/MS analysis of hCB2R TMH6 model peptide, either not exposed to AM-841 (panel a) or incubated with AM-841 prior to analysis (panel b). Mass shifts demonstrating covalent labeling of the peptide’s cysteine (Cys) residue by AM-841 are indicated.
Figure 3
Figure 3
Multiplex MRM-MS analysis of FLAG-hCB2R-6His tryptic digests. (a) Spectra for each of the seven hCB2R TMHs are shown, with the respective GRAVY hydrophobicity score indicated. A propensity for one missed cleavage in TMH6 is demonstrated. (b) Incubation of purified FLAG-hCB2R-6His with AM-841 reduces the TMH6-associated signal intensity by ~ 75% (red spectrum) with respect to the signal intensity of TMH6 (blue spectrum) from naïve receptor not exposed to AM-841, whereas the spectral intensities of the other TMHs remained unchanged after holoreceptor incubation with AM-841 (as exemplified by TMH1).
Figure 4
Figure 4
High-resolution Q-TOF MS/MS spectra of the hCB2R TMH6 peptide with one missed cleavage (LAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVK) obtained from analysis of tryptic digests of (a) purified FLAG-hCB2R-6His itself (monoisotopic m/z = 977.31754+) or (b) purified FLAG-hCB2R-6His that had been incubated with AM-841 (monoisotopic m/z = 1074.37574+). The mass difference is equivalent to the mass of AM-841.
Figure 5
Figure 5
High-resolution MS/MS fragmentation spectra of the hCB2R TMH6 peptide with one missed cleavage (LAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVK) obtained from analysis of tryptic digests of (a) purified FLAG-hCB2R-6His itself in which C6.47(257) was carbamidomethylated [Cys(257)-CAM] or (b) purified FLAG-hCB2R-6His that had been incubated with AM-841. The mass shift at the y-22 ion demonstrates covalent labeling of the hCB2R y-22 cysteine residue, C6.47(257), by AM-841.
Figure 6
Figure 6
Schematic illustration of the reaction between AM-841 and the -SH moiety of hCB2R C6.47(257). R′ and R″ denote the portions of the TMH6 peptide chain flanking the reactive C6.47(257) residue.

Similar articles

Cited by

References

    1. Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro. Endocrinol. Lett. 2009;30:153–179. - PubMed
    1. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic application. Pharmacol. Res. 2009;60:77–84. - PubMed
    1. Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr. Med. Chem. 2010;17:1468–1486. - PMC - PubMed
    1. Demuth DG, Molleman A. Cannabinoid signaling. Life Sci. 2006;78:549–563. - PubMed
    1. Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin. Emerg. Drugs. 2009;14:43–65. - PubMed

Publication types